Concealed Drug Trial Results Mislead Doctors & Put Children’s Lives at Risk – NYT Thu, 22 Jul 2004 The inordinate influence that drug companies wield on government healthcare regulatory policies–through campaign contributions to elected officials and lucrative job offers to public officials–has seriously compromised children’s safety in numerous ways. An…
Drug safety Hearings-Sept-Congress/ FDA – Lilly Plans to Disclose Data Tue, 3 Aug 2004 A hearing about the possible connection between suicide and antidepressant drugs will be held on Aug 4, by the California Senate by Sen. Tom Torkalson, chairman of the Senate Task Force on Youth and Workplace Wellness…
FDA’s Double Standard Re: Advisory Committee Membership Mon, 15 Nov 2004 FDA’s inexplicable actions–the latest being the removal of Dr. Curt Furberg from an FDA advisory committee for alleged "intellectual conflict of interest" – demonstrate hypocracy and intellectual dishonesty. Dr. Furberg independently analyzed the scientific data, concluding: "The result is…
NIH Under Fire: Longtime Favorite of Congress – Wash Post / WSJ Sun, 27 Jun 2004 Under fire from Congress with evidence of NIH staff engaging in secret outside contracts and consultancies, NIH Director, Dr. Elias Zerhouni, turned a corner. He acknowledged the problem at a hearing (June 22) of…
Go Slow on Mental Health Screening: Dr. Karen Effrem responds to New Freedom Commission Chair, Michael Hogan – Wash Times Sun, 31 Oct 2004 A letter to the editor in the Washington Times – Go slow on Mental Health Screening – by AHRP’s newest board member, pediatrician Dr. Karen Effrem,…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Natrecor found to worsen kidney function, hasten death – NYT Tue, 17 May 2005 Natrecor, a drug approved by the FDA for treating patients with heart failure, is being widely prescribed off label for unapproved uses. The drug is prescribed for so-called “tune-ups” in outpatient clinics – although that use…
Protecting Editorial Integrity – Dr. Stefan Kreuszewski BMJ Sun, 6 Feb 2005 In his BMJ editorial, “A tough nut to crack,” Kamran Abassi writes: “The drug industry considers the BMJ a tough nut to crack,” an insider recently told us. Publishing a “favourable” research paper is far trickier in the…
What the FDA Isn’t Telling You – SLATE Date: Tue, 27 Sep 2005 Writing in SLATE, Jeanne Lenzer has uncovered evidence demonstrating FDA culpability in helping drug manufacturers conceal vital, life-saving information from the public. In this case, undisclosed suicides in clinical trials testing Eli Lilly’s drug, duloxetine (trade names:…
FDA Tones Down Warning–Shyra Kallas an SSRI Suicide Victim Fri, 4 Mar 2005 In his recent testimony before the Senate Health, Education, Labor, and Pensions committee, Dr. David Fassler, representing the American Psychiatric Association (APA) and the American Academy of Child and Adolescent Psychiatry (AACAP), misrepresented the scientific facts about…
NIH: Public Servant or Private Marketer? NIH Seeks Outside Inquiry of Alzheimer’s researcher conflicts of interest – LAT Mon, 31 Jan 2005 A year after the Los Angeles Times published its first an in-depth investigative report documenting in detail evidence of major conflicts of interest by top scientists at the…
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…
